Glucocorticosteroids for primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Primary biliary cirrhosis is a chronic progressive cholestatic liver disease of presumed autoimmune etiology, characterised by the destruction of small intrahepatic bile ducts and the eventual development of cirrhosis and liver failure. Its progression may be influenced by immunosuppression. Glucocorticosteroids are potent immunosuppressive agents, but they are associated with significant adverse effects, including osteoporosis. OBJECTIVES: To systematically evaluate the beneficial and harmful effects of glucocorticosteroids versus placebo or no intervention for patients with primary biliary cirrhosis. SEARCH STRATEGY: The Cochrane Hepato-Biliary Controlled Trials Register,The Cochrane Library, MEDLINE, EMBASE, and the full text of the identified studies were searched until June 2004. The search strategy included terms for primary biliary cirrhosis and glucocorticosteroids (including the names of frequently used preparations). Previous research groups and manufacturers were contacted for additional references. No language restrictions were applied. SELECTION CRITERIA: Double-blind, single-blind, or unblinded randomised clinical trials evaluating any preparation of glucocorticosteroids versus placebo or no intervention in patients with primary biliary cirrhosis diagnosed by abnormal liver function tests and either anti-mitochondrial antibodies or histology were included. Additional agents were allowed if they were administered to both groups equally. DATA COLLECTION AND ANALYSIS: The quality of the randomised clinical trials was evaluated by methodology components (generation of allocation sequence; allocation concealment; blinding; follow up). Analyses were performed according to the intention-to-treat method with missing data being accounted for by imputation. MAIN RESULTS: Only two underpowered trials (reporting 36 and 40 patients) were identified. These differed markedly in their inclusion criteria and treatment protocols. Both stated that they used placebo. However, allocation concealment was unclear. Only one trial reported any patient deaths. No significant improvement in mortality was identified (odds ratio (OR) 0.42, 95% confidence interval (CI) 0.10 to 1.76). Improvements in serum markers of liver inflammation and liver histology were identified. Potentially prognostically linked markers such as bilirubin and albumin were incompletely reported. Bone mineral density (weighted mean difference -2.84%, 95% CI -4.16 to -1.53) and the number of patients with any adverse event (OR 8.99, 95% CI 2.15 to 37.58) were significantly increased in the glucocorticosteroid group. AUTHORS' CONCLUSIONS: There is insufficient data to support or reject the use of glucocorticosteroids for patients with primary biliary cirrhosis. It may be appropriate to consider a large prospective randomised clinical trial on this topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Randomized trial of chlorambucil for primary biliary cirrhosis
Hoofnagle, J. H., Davis, G. L., Schafer, D. F., Peters, M., Avigan, M. I., Pappas, S. C., Hanson, R. G., Minuk, G. Y., Dusheiko, G. M., Campbell, G., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90183-6 · Cited by 157
Leuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80327-8 · Cited by 119
Kilmurry, M. R., Heathcote, E. J., Cauch-Dudek, K., O’Rourke, K., Bailey, R. J., Blendis, L. M., Ghent, C. N., Minuk, G. Y., Pappas, S. C., Scully, L. J., et al. (1996) · Hepatology · doi:10.1002/hep.510230532 · Cited by 94
Cited by
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Mayo, M. J., Wigg, A. J., Leggett, B. A., Arnold, H., Thompson, A. J., Weltman, M., Carey, E. J., Muir, A. J., Ling, L., Rossi, S. J., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1209 · Cited by 125
Diagnosis and Management of Cirrhosis-Related Osteoporosis
Santos, L. A. A., & Romeiro, F. G. (2016) · BioMed Research International · doi:10.1155/2016/1423462 · Cited by 66
Glucocorticoids have opposing effects on liver fibrosis in hepatic stellate and immune cells
Kim, K. H., Lee, J. M., Zhou, Y., Harpavat, S., & Moore, D. D. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1029 · Cited by 41
Metadata
- Authors
- Prince, M., Christensen, E., & Gluud, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2005-04-20
- Volume
- 2010
- Issue
- 1
- Pages
- CD003778-CD003778
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1927872952
- Cited by
- 28
- References
- 7
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.